on Medicines: This law sets the fundamental principles for the development, registration, and monitoring of medicinal products.

Resolution of the Cabinet of Ministers of Ukraine No. 667: This resolution outlines specific regulations pertaining to the state registration of medicines and biosimilars.

SMDC Guidelines: The SMDC provides specific guidelines regarding the technical requirements for the registration of biosimilars and biologics, including pharmacovigilance expectations.

Engaging with these documents allows regulatory professionals to pinpoint critical areas that necessitate strict compliance, including the definition of biosimilars, required documentation, and safety monitoring frameworks. Understanding the terminologies and legal definitions applied to biosimilars versus traditional biologics is imperative in navigating the regulatory landscape effectively. It is also essential to stay updated on any changes or amendments to existing regulations, as these may affect submission timelines and post-market surveillance obligations.

Step 2: Dossier Preparation for Biosimilars

Once familiar with the regulatory framework, the next step lies in preparing the regulatory dossier essential for the registration of biosimilars and biologics in Ukraine. The dossier must adhere to the specific structure and content requirements stipulated by the SMDC. A comprehensive and meticulously assembled dossier can significantly affect the success of the registration process.

The dossier typically includes the following critical components:

• Administrative Information: This section should contain details of the applicant, manufacturing sites, and responsible parties involved in the development and marketing of the product.
• Quality Data: Quality information is paramount, including the detailed characterization of the biosimilar, a comprehensive description of the manufacturing process, and the raw materials used. Moreover, it should include data from stability testing and validation of the manufacturing process.
• Non-Clinical and Clinical Data: Evidence of biosimilarity to the reference product must be provided through well-designed clinical trials. This section should encompass pharmacokinetic, pharmacodynamic, and safety data collected from specific studies as per the SMDC guidelines.
• Pharmacovigilance Plan: A robust pharmacovigilance plan detailing the methods and tools for ongoing monitoring and risk minimization after the product reaches the market. This is a pivotal part of the dossier aimed at ensuring drug safety in conjunction with regulatory expectations.

In preparing the quality and safety documentation, special attention should be devoted to demonstrating bioequivalence through comparative analyses with the reference biologic. The evidence should clearly support the assertion that the biosimilar has no clinically meaningful differences from the reference product in terms of safety, purity, and potency.

Regulatory teams should also consider utilizing project management tools for dossier development and review processes to ensure that all necessary information is compiled cohesively. Additionally, it is beneficial to consult with external regulatory experts if internal expertise in certain detailed technical areas is limited.

Step 3: Submission of the Application

After the regulatory dossier is compiled and finalized, the next and pivotal step is the actual submission of the application to the SMDC for evaluation. The submission process involves several critical actions that must be executed with precision to avoid delays or rejections.

The following actions should be undertaken:

• Pre-Submission Consultation: Prior to formal submission, it is advisable to engage the SMDC in a pre-submission consultation meeting. This meeting can provide insights into expectations and allow for preliminary feedback regarding the data submitted in the dossier.
• Electronic Submission: The current trend, aligning with global practices, is to submit applications electronically. Ensure that the dossier is formatted according to the prescribed electronic submissions guidelines, which may include specific file formats, organization of documents, and metadata requirements.
• Official Application Form: Complete all required forms diligently, ensuring accuracy in every detail. Errors in administrative information can lead to delays in the evaluation process.
• Payment of Fees: Accompany the submission with the necessary fees as stipulated by the SMDC. Ensure that payment verification is included in the application package.

Upon successful submission, it is essential to maintain communication with the SMDC throughout the review process. Tracking the application status may involve regular follow-ups unless the agency designates a specific point of contact for inquiries. Establishing a system for noting timelines of submission may also aid in planning subsequent activities surrounding potential post-approval commitments dictated by the review outcome.

Step 4: Review Process and Considerations

Upon submission, the SMDC will enter the dossier into the review process, which is a critical stage where the application is thoroughly evaluated based on scientific and regulatory standards. Understanding the components and timeline of this review process can prepare regulatory teams for anticipated outcomes and possible challenges.

The review process generally encompasses:

• Document Assessment: Reviewers will meticulously examine all aspects of the submission, including the quality, non-clinical, and clinical data presented. They will assess whether the provided evidence adequately supports the claims of biosimilarity and compliance with regulatory standards.
• Advisory Committee Involvement: In complex cases, there might be a need for an advisory committee to assess the application further. Their expert opinions can influence approval outcomes and address any contentious or unclear areas in the dossier.
• Requests for Additional Information: During the review, the SMDC may issue requests for additional documentation or clarification. It is crucial to respond promptly and thoroughly to these requests to avoid extensions that could delay approvals.

The duration of the review process can vary significantly based on the complexity of the application and any deficiencies identified. Regulatory professionals should maintain flexibility in project timelines and prepare for potential delays while ensuring that all responses to regulatory inquiries are comprehensively documented.

Step 5: Post-Approval Pharmacovigilance Commitments

Once the application is approved, the focus shifts to pharmacovigilance commitments and compliance with post-market obligations to ensure drug safety and efficacy in the long term. Pharmacovigilance is a significant regulatory pillar demanding ongoing attention and commitment from the marketing authorization holder (MAH).

The key components of post-approval pharmacovigilance include:

• Risk Management Plan (RMP): An approved risk management plan should guide the systematic identification and assessment of any potential risks associated with the medicinal product. This plan should encompass risk minimization strategies and methods for proactively capturing adverse events.
• Adverse Event Reporting: Establish robust mechanisms for adverse event reporting and the prompt communication of safety issues to the SMDC. The process should include training mechanisms for healthcare professionals to identify and report adverse events in a manner compliant with regulatory expectations.
• Periodic Safety Update Reports (PSURs): Regularly prepare and submit PSURs to the SMDC. PSURs should provide an overview of the safety data concerning the product, assessed against the available benefit-risk profile.
• Ongoing Risk Assessment: Commit to continuous monitoring and assessment of emerging safety data, including real-world evidence, ensuring adjustments in the RMP as needed based on the evolving benefit-risk landscape.

Collaboration with regulatory and PV experts is vital in establishing and maintaining a robust pharmacovigilance system. This collaboration extends to leveraging modern technology and databases for effective signal detection and managing data surrounding adverse event reports accurately. In doing so, the MAH demonstrates compliance with the ongoing regulatory obligations as defined by the SMDC and upholds the highest standards of patient safety.

Conclusion

Navigating the regulatory pathway for biosimilars and biologics in Ukraine necessitates a thorough understanding of the regulatory framework, diligent dossier preparation, strategic engagement with the SMDC throughout submission and review processes, and a firm commitment to post-approval pharmacovigilance practices. By adhering to these outlined steps, regulatory professionals can optimize their submissions and foster patient safety in the post-market landscape.

Further exploration of state-specific literature and guidelines, including resources from ICH, will provide invaluable context and continual updates about expectations in pharmacovigilance and other regulatory aspects pertinent to biosimilars and biologics.